A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy

EML4-ALK fusion represents a bona fide oncogene driver and molecular target in non-small-cell lung cancer (NSCLC), and ALK-targeted therapy has demonstrated clear clinical utility for NSCLC patients with an ALK fusion gene aberration. First reported in 2007, EML4-ALK gene rearrangement was more prevalent in adenocarcinoma patients with a prevalence of approximately 2 –13% [1,2]. The recommended methods for detection of ALK rearrangement include Ventana D5F3 ALK immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR), all of which have shown high concordance in lung adenocarcinoma (LADC) patients [3–7].

Source: Lung Cancer - February 18, 2019 Category: Cancer & Oncology Authors: Haiyue Wang, Leina Sun, Yaxiong Sang, Xin Yang, Guangming Tian, Ziping Wang, Jian Fang, Wei Sun, Lixin Zhou, Ling Jia, Ming-Sound Tsao, Huaiyin Shi, Dongmei Lin Source Type: research